Literature DB >> 22252777

Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas.

Keith M Skubitz1, Princy Francis, Amy P N Skubitz, Xianghua Luo, Mef Nilbert.   

Abstract

BACKGROUND: Metastatic propensity of soft tissue sarcoma (STS) is heterogeneous and may be determined by gene expression patterns that do not correlate well with morphology. The authors have reported gene expression patterns that distinguish 2 broad classes of clear cell renal carcinoma (ccRCC-gene set), and other patterns that can distinguish heterogeneity of serous ovarian carcinoma (OVCA-gene set) and aggressive fibromatosis (AF-gene set); however, clinical follow-up data were not available for these samples.
METHODS: In the current study, gene expression patterns in 73 samples of high-grade STS were examined using spotted cDNA microarray slides that contained ∼16,000 unique UniGene clusters. Approximately 50% of the genes present in the ccRCC-, OVCA-, and AF-gene sets were also represented in the data from this chip set, and these were combined to form a composite gene set of 278 probes.
RESULTS: Hierarchical clustering using this composite gene set suggested the existence of subsets of the STS samples. Analysis revealed differences in the time to development of metastatic disease between the clusters defined by the first branch point of the clustering dendrogram (P = .005), and also among the 4 different clusters defined by the second branch points (P = .001).
CONCLUSIONS: This approach suggests the existence of >2 subsets of high-grade pleomorphic STS, each with distinct clinical behavior. A composite gene set such as that described here may be useful to stratify STS in clinical trials, and may be of practical utility in patient management.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22252777     DOI: 10.1002/cncr.26733

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

Review 2.  MicroRNAs in the pathobiology of sarcomas.

Authors:  Anne E Sarver; Subbaya Subramanian
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

3.  Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas.

Authors:  Keith M Skubitz; Amy P N Skubitz; Wayne W Xu; Xianghua Luo; Pauline Lagarde; Jean-Michel Coindre; Frédéric Chibon
Journal:  J Transl Med       Date:  2014-06-20       Impact factor: 5.531

4.  Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors.

Authors:  Keith M Skubitz; Kate Geschwind; Wayne W Xu; Joseph S Koopmeiners; Amy P N Skubitz
Journal:  J Transl Med       Date:  2016-02-13       Impact factor: 5.531

Review 5.  The roles of metallothioneins in carcinogenesis.

Authors:  Manfei Si; Jinghe Lang
Journal:  J Hematol Oncol       Date:  2018-08-23       Impact factor: 17.388

6.  PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.

Authors:  François Bertucci; Pascal Finetti; Audrey Monneur; Delphine Perrot; Christine Chevreau; Axel Le Cesne; Jean-Yves Blay; Olivier Mir; Daniel Birnbaum
Journal:  Mol Oncol       Date:  2019-06-07       Impact factor: 6.603

7.  Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi-centre study.

Authors:  Maria A Smolle; Angelika Schaffler; Andreas Leithner; Veroniek M Van Praag; Marko Bergovec; Joanna Szkandera; Bernadette Liegl-Atzwanger; Maya Niethard; Per-Ulf Tunn; Michiel Van De Sande; Dimosthenis Andreou
Journal:  J Surg Oncol       Date:  2020-01-31       Impact factor: 3.454

8.  Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.

Authors:  Vincent Niziers; Alexandre de Nonneville; Pascal Finetti; Francois Bertucci; Léna Mescam; Olivier Mir; Antoine Italiano; Axel Le Cesne; Jean-Yves Blay; Michele Ceccarelli; Davide Bedognetti; Daniel Birnbaum; Emilie Mamessier
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

9.  Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas.

Authors:  Navid Sadri; Paul J Zhang
Journal:  Cancers (Basel)       Date:  2013-04-02       Impact factor: 6.639

10.  Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma".

Authors:  Fergal C Kelleher; Antonella Viterbo
Journal:  Cancers (Basel)       Date:  2013-02-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.